Canine and Feline Protein-Losing Enteropathy: Diagnostic and Management Approach

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Protein-losing enteropathy (PLE) is a syndrome of excessive gastrointestinal protein loss, primarily manifesting as hypoalbuminemia, and requires a stepwise diagnostic approach to differentiate from protein-losing nephropathy and hepatic insufficiency. Initial assessment includes a minimum database (serum albumin, globulins, cholesterol, calcium, BUN, liver enzymes, urinalysis with protein:creatinine ratio) to guide exclusion of non-enteric causes.
• Exclusion of renal and hepatic protein loss is paramount before pursuing intestinal diagnostics; a normal urine protein:creatinine ratio (<0.5 in dogs) and unremarkable liver function tests (bile acids, enzymes) are critical. Fecal alpha-1-proteinase inhibitor concentration serves as a confirmatory test for enteric protein loss, though its interpretation requires species-specific reference intervals and consideration of sampling adequacy.
• Abdominal ultrasonography is vital for assessing intestinal wall layering, mucosal echogenicity (hyperechoic striations suggestive of PLE), and lymphadenomegaly, but definitive etiologic diagnosis necessitates histopathology obtained via endoscopic or full-thickness intestinal biopsy.
• Prognostic indicators for PLE include the severity of hypoalbuminemia, clinical activity index scores (CIBDAI/CCECAI), clonal lymphocyte rearrangement (indicating potential lymphoma), and vitamin D status (hypovitaminosis D is associated with poor outcome).
• Canine PLE is frequently associated with chronic inflammatory enteropathy and intestinal lymphangiectasia, while feline PLE is less common and often linked to chronic inflammatory enteropathy or alimentary lymphoma, necessitating a lower threshold for considering neoplasia in cats.
• Recognized complications include thromboembolic disease due to hypercoagulability (loss of antithrombin III) and hypovitaminosis D, which carries significant prognostic weight and warrants routine assessment and supplementation.

Protein-losing enteropathy (PLE) is a syndrome of excessive gastrointestinal protein loss that results in panhypoproteinemia, most conspicuously hypoalbuminemia. This article provides a stepwise diagnostic framework for PLE in dogs and cats, with emphasis on differentiating enteric protein loss from protein-losing nephropathy and hepatic insufficiency. The intended reader is the practicing veterinarian who requires a structured approach to the hypoalbuminemic patient with suspected gastrointestinal disease. The article covers the physiologic basis of enteric protein loss, the diagnostic workup from minimum database through intestinal biopsy, and the prognostic indicators that inform case management. Detailed dietary management is excluded from this reference.

The diagnostic challenge in PLE is twofold. First, the clinical signs are nonspecific and may be absent entirely in early disease. Second, the differential diagnosis for hypoalbuminemia extends well beyond the gastrointestinal tract. A disciplined, sequential approach that excludes renal and hepatic protein loss before pursuing intestinal investigation will prevent diagnostic error and unnecessary procedures. This framework is applicable to both dogs and cats, although important species differences in disease prevalence and histopathologic patterns exist and are highlighted throughout.

At a Glance

Pathophysiology of Enteric Protein Loss

The gastrointestinal tract maintains protein homeostasis through a dynamic balance of absorption, secretion, and cellular turnover. Plasma proteins, particularly albumin, leak into the intestinal lumen continuously at a low baseline rate. This loss is normally negligible because luminal proteins are digested and their constituent amino acids reabsorbed. PLE develops when this balance is disrupted by one of three general mechanisms: lymphatic obstruction or dysfunction, mucosal inflammation with increased permeability, or erosive and ulcerative disease that allows direct protein exudation.

Lymphatic disease is a dominant mechanism in dogs. Intestinal lymphangiectasia, whether primary or secondary to inflammatory infiltration, impairs the return of chyle and protein-rich lymph to the systemic circulation. The pathophysiology of lymphatic disease remains incompletely understood, and the relationship between lymphangiectasia and inflammatory bowel disease in dogs is not fully resolved. In people, PLE is usually associated with primary intestinal lymphangiectasia, whereas in dogs PLE is most often a feature of inflammatory bowel disease and less frequently intestinal lymphangiectasia, although it is not proven which process is the true driving defect. The mechanisms of enteric protein loss are identical in dogs and people irrespective of the underlying cause.

Mucosal inflammation increases protein loss through several pathways. Tight junction disruption allows paracellular leakage of plasma proteins. Increased epithelial apoptosis and sloughing expose subepithelial capillaries. Inflammatory mediators also promote lymphatic endothelial dysfunction, blurring the distinction between inflammatory and lymphatic mechanisms. Crypt disease, including crypt abscessation and crypt dilation, contributes to protein loss in some dogs and may represent a distinct histopathologic entity.

Species Differences in Disease Expression

Canine PLE occurs most commonly in the setting of chronic inflammatory enteropathy, with intestinal lymphangiectasia as a frequent concurrent or alternative diagnosis. Certain breeds appear predisposed, including Yorkshire Terriers, in which a distinct PLE phenotype has been described. A retrospective study of 30 Yorkshire Terriers with PLE found that females outnumbered males, the median age at diagnosis was 7 years, and common clinical signs included diarrhea, vomiting, ascites, and respiratory difficulty. Histopathologic abnormalities included villous lymphatic dilatation, crypt lesions, villous stunting, and variable increases in lamina propria cellularity.

Feline PLE is relatively rare compared with dogs. The syndrome in cats is most often associated with chronic inflammatory enteropathy, alimentary lymphoma, or both. The diagnostic approach in cats must therefore include a lower threshold for considering intestinal neoplasia, particularly in older animals. The prognostic implications differ substantially between inflammatory and neoplastic causes, making histopathologic diagnosis essential.

Clinical Presentation and Initial Assessment

The clinical signs of PLE reflect both the underlying intestinal disease and the consequences of hypoproteinemia. Diarrhea is common but not universal. Vomiting, weight loss, and inappetence occur frequently. Ascites and peripheral edema develop when plasma oncotic pressure falls sufficiently to permit transudation of fluid into body cavities and interstitial spaces. Respiratory difficulty may result from pleural effusion, as observed in the Yorkshire Terrier cohort in which respiratory difficulty was reported in 8 of 30 dogs.

Physical examination findings are often nonspecific. Poor body condition, muscle wasting, and palpable abdominal effusion may be present. The clinician should specifically assess for jugular venous distension or hepatomegaly that would suggest right-sided heart failure as an alternative cause of both ascites and enteric protein loss. Cardiac disease can produce PLE through increased central venous pressure and impaired lymphatic drainage, and this mechanism should not be overlooked in the initial assessment.

The minimum database for any hypoalbuminemic patient includes a complete blood count, serum biochemistry profile, and urinalysis. Serum albumin below the reference interval with concurrent reduction in globulins supports gastrointestinal loss, whereas isolated hypoalbuminemia with normal globulins is more typical of renal loss. Hypocholesterolemia is a common finding in PLE and reflects concurrent intestinal loss of lipoproteins. Hypocalcemia occurs in some patients, attributed to binding of calcium by albumin and to vitamin D malabsorption. A study of 43 dogs with PLE found that low serum 25-hydroxyvitamin D concentration was significantly associated with poor outcome, supporting assessment of vitamin D status as part of the initial evaluation.

Excluding Protein-Losing Nephropathy and Hepatic Insufficiency

Before pursuing gastrointestinal diagnostics, the clinician must exclude the two principal alternative causes of hypoalbuminemia. Protein-losing nephropathy is excluded by urinalysis with assessment of urine protein:creatinine ratio. A ratio within the reference interval effectively rules out glomerular protein loss as the cause of hypoalbuminemia. Hepatic insufficiency is assessed through serum bile acids, either fasting or postprandial, and through evaluation of liver enzyme activities and bilirubin. Hepatic synthetic failure typically produces concurrent reductions in albumin, urea, cholesterol, and glucose, although the pattern varies with the underlying hepatopathy.

The order of testing matters. A urinalysis is inexpensive and immediately available, and it should be performed in every hypoalbuminemic patient. If the urine protein:creatinine ratio is normal and liver function testing is unremarkable, the gastrointestinal tract becomes the presumptive source of protein loss. This sequence prevents the common error of pursuing intestinal biopsy in a patient with undiagnosed glomerular disease.

Stepwise Diagnostic Framework for Suspected Protein-Losing Enteropathy

The diagnostic approach proceeds through three phases: confirmation that gastrointestinal loss is the cause of hypoalbuminemia, identification of the underlying intestinal disease, and assessment of severity and prognostic markers. Each phase changes the index of suspicion for specific differentials and determines how aggressively to pursue tissue diagnosis.

Phase 1: Confirming the Gastrointestinal Source

Once protein-losing nephropathy and hepatic insufficiency are excluded, the clinician must demonstrate that the gastrointestinal tract is the site of protein loss. This is largely inferential in clinical practice. Panhypoproteinemia, with concurrent decreases in albumin and globulins, supports gastrointestinal loss because the liver synthesizes both fractions and renal loss preferentially removes albumin. A normal urinalysis with inactive sediment and a urine protein-to-creatinine ratio below 0.5 effectively rules out glomerular disease in dogs. Hepatic insufficiency is excluded by normal pre- and postprandial bile acids, normal resting ammonia, and absence of microhepatia or other ultrasonographic hepatic abnormalities.

Serum alpha-1-proteinase inhibitor (alpha-1-PI) measurement remains the definitive confirmatory test for enteric protein loss. Fecal alpha-1-PI concentration reflects intestinal protein leakage because the molecule resists degradation in the gut lumen. The test requires a fasting sample of fresh feces, ideally collected over three consecutive days, and results must be interpreted against species-specific reference intervals. A normal fecal alpha-1-PI does not exclude PLE, particularly if sampling occurred after a period of reduced dietary intake or if the lesion is intermittent. In cats, the test is less well validated and the reference interval differs from dogs.

Phase 2: Laboratory Assessment and Inflammatory Markers

A complete blood count, serum biochemistry profile, and urinalysis form the minimum database. Specific findings refine the differential list. Lymphopenia is common in dogs with intestinal lymphangiectasia due to lymphatic loss of lymphocytes. Monocytosis at presentation was associated with poorer response to treatment in one cohort of Yorkshire Terriers with PLE Simmerson et al., 2014. Hypocalcemia occurs from both albumin-bound calcium loss and vitamin D malabsorption. Ionized calcium should be measured directly because total calcium underestimates the physiologically relevant fraction. Low serum 25-hydroxyvitamin D concentration at diagnosis was significantly associated with negative outcome within four months in a retrospective study of 43 dogs with PLE Allenspach et al., 2017.

Serum cobalamin and folate provide localizing information. Low cobalamin with normal folate suggests distal small intestinal disease, while low folate with normal cobalamin implicates the proximal small intestine. Both are frequently decreased in severe diffuse disease. Cobalamin supplementation is indicated when concentrations are low, regardless of the underlying diagnosis.

Phase 3: Differentiating Pancreatic Insufficiency

Exocrine pancreatic insufficiency (EPI) can produce hypoalbuminemia and chronic diarrhea that mimics PLE. The distinction matters because EPI is managed with enzyme replacement instead of immunosuppression. Serum trypsin-like immunoreactivity (TLI) is the discriminating test. Canine TLI below the reference interval confirms EPI, while normal or elevated values direct attention to the intestine. Feline TLI is interpreted similarly. A practical approach is to measure TLI early in the workup of any dog with chronic diarrhea and hypoalbuminemia, particularly in breeds predisposed to EPI such as German Shepherd Dogs and rough-coated Collies. Concurrent measurement of cobalamin and folate is reasonable because EPI frequently coexists with small intestinal dysbiosis.

Phase 4: Imaging and Its Limitations

Abdominal ultrasonography serves three purposes: exclude extraintestinal disease, characterize intestinal wall changes, and guide biopsy sampling. The finding of hyperechoic mucosal striations had a sensitivity of 75% and a specificity of 96% for PLE in dogs with chronic diarrhea, whereas normal hypoechoic mucosa was more consistent with food-responsive disease Gaschen et al., 2008. Intestinal wall thickness alone is neither sensitive nor specific for inflammation and should not be used to confirm or exclude PLE. Ultrasonographic findings of peritoneal effusion, mesenteric lymphadenomegaly, and thickened jejunal walls support the diagnosis but do not establish a specific etiology.

The choice between endoscopic and full-thickness biopsy depends on lesion distribution and patient stability. Endoscopic biopsies sample the mucosa and superficial submucosa and are adequate for diffuse inflammatory disease. Full-thickness biopsies are preferred when ultrasound identifies a focal mass, when lymphangiectasia is suspected because dilated lacteals may be deeper than endoscopic biopsy depth, or when endoscopic samples are nondiagnostic. In cats, full-thickness biopsy carries higher anesthetic and surgical risk, and endoscopic sampling is often attempted first. Histopathology should be interpreted using the World Small Animal Veterinary Association gastrointestinal classification system to standardize reporting Simmerson et al., 2014.

Phase 5: Prognostic Stratification

Several variables at diagnosis predict outcome and inform client communication. The canine inflammatory bowel disease activity index (CIBDAI) and canine chronic enteropathy clinical activity index (CCECAI) score clinical signs, higher scores at diagnosis and failure to normalize within 50 days of treatment were associated with shorter survival in a cohort of 92 dogs Nakashima et al., 2015. Clonal rearrangement of lymphocyte antigen receptor genes, detected by PCR for antigen receptor rearrangement (PARR), independently predicted mortality, reflecting the inclusion of intestinal lymphoma among PLE cases. Elevated blood urea nitrogen at diagnosis also carried independent prognostic weight, likely reflecting dehydration, gastrointestinal hemorrhage, or reduced hepatic synthetic function.

Histopathologic diagnosis stratifies prognosis. In the same cohort, both small-cell and large-cell lymphoma were associated with significantly shorter survival than chronic enteritis or intestinal lymphangiectasia Nakashima et al., 2015. Yorkshire Terriers with PLE showed a median survival of 44 months in responders to glucocorticoid therapy versus 12 months in nonresponders, with four dogs experiencing peracute death Simmerson et al., 2014. Peracute death in this breed has been attributed to thromboembolic complications, although the mechanism is not fully characterized.

Differentiating Gastrointestinal, Renal, and Hepatic Hypoalbuminemia

Documentation and Monitoring

Medical records should capture the diagnostic sequence explicitly, including the exclusion of renal and hepatic disease, the results of TLI and fecal alpha-1-PI, ultrasonographic findings, and biopsy histopathology with WSAVA grading. Serial monitoring should track body weight, serum albumin, CIBDAI or CCECAI score, and ionized calcium. Recheck albumin at two to four weeks after treatment initiation, then at eight to twelve weeks. Failure of albumin to rise within 50 days of treatment warrants reassessment of the diagnosis, particularly reconsideration of intestinal lymphoma versus inflammatory disease Nakashima et al., 2015. Vitamin D status should be assessed at diagnosis given its prognostic association, and supplementation considered when deficiency is documented Allenspach et al., 2017.

Recognized Complications and Early Detection

The most consequential complication in protein-losing enteropathy is thromboembolic disease. Hypercoagulability arises from loss of antithrombin III alongside albumin, and affected dogs may present with acute dyspnoea, collapse, or pelvic limb paresis from pulmonary or aortic thromboembolism. Detection relies on maintaining a low threshold for thoracic imaging and blood gas assessment in any PLE patient with sudden respiratory deterioration. Peracute death occurs in a subset of dogs, and in one retrospective series of Yorkshire Terriers with PLE, four of 23 dogs with follow-up died peracutely despite treatment Simmerson et al., clinical features and outcome in Yorkshire Terrier PLE.

Hypovitaminosis D is common and carries prognostic weight. Low serum 25-hydroxyvitamin D concentration at diagnosis was significantly associated with poor outcome in a retrospective study of 43 dogs, with negative outcome defined as death from PLE within four months Allenspach et al., hypovitaminosis D and outcome in canine PLE. Routine measurement of 25(OH)D at diagnosis is therefore advisable, and supplementation should be considered as part of supportive care.

Ascites and pleural effusion may develop rapidly and require therapeutic drainage when they compromise respiration. Hypocalcemia, when present, is usually ionised and may be subclinical, serial ionised calcium monitoring is preferred over total calcium, which is confounded by albumin concentration. Folate and cobalamin status should be reassessed during treatment, as ongoing loss and malabsorption can produce deficiencies that limit intestinal healing.

Common Diagnostic Errors and Corrective Actions

A common error is treating hypoalbuminaemia with albumin infusion before establishing the source of loss. This is rarely durable and can obscure the diagnostic picture. Another is proceeding to intestinal biopsy without first documenting a negative urine protein:creatinine ratio and normal bile acid profile, which risks misclassifying renal or hepatic disease as PLE. Less experienced clinicians may also misinterpret mild intestinal wall thickening as definitive evidence of inflammatory bowel disease, when ultrasound findings are neither specific nor sensitive for inflammation Gaschen et al., ultrasonographic findings and CIBDAI in canine chronic enteropathies.

Limitations of the Evidence and Areas of Disagreement

The evidence base for PLE is dominated by retrospective canine studies with small sample sizes and inconsistent outcome definitions. The syndrome is relatively rare in cats, and published guidance for feline PLE is extrapolated largely from canine data Craven and Washabau, comparative pathophysiology and management of PLE. Whether lymphatic disease is the primary driving defect or a secondary consequence of inflammation remains unresolved, and this uncertainty affects treatment choices.

Expert opinion differs on the role of dietary fat restriction versus immunosuppression as first-line therapy. Some clinicians favour aggressive immunosuppression from the outset, while others argue that lymphatic disease responds better to dietary modification. Prognostic scoring systems such as the canine inflammatory bowel disease activity index have been associated with survival in multivariate analysis Nakashima et al., prognostic factors in canine PLE, but their utility in individual patients is limited by overlap between groups. Clonal lymphocyte antigen receptor rearrangement carries prognostic weight but does not always correlate with histopathologic diagnosis, and interpretation requires care.

Referral, Specialist Consultation, and Laboratory Involvement

Referral to an internal medicine specialist is warranted when endoscopic biopsy is not feasible, when histopathology is non-diagnostic, when the patient fails to respond to an appropriate treatment trial, or when the clinician is not equipped to manage complications such as thromboembolism or refractory ascites. Specialist centers can offer advanced imaging, including computed tomography lymphangiography, and can perform full-thickness intestinal biopsy when endoscopic sampling is inadequate.

Laboratory involvement extends beyond routine biochemistry. Antithrombin III activity, ionised calcium, 25-hydroxyvitamin D, cobalamin, folate, and pancreatic lipase immunoreactivity should be measured at baseline. If clonal rearrangement testing is considered, the laboratory should be consulted before sampling to ensure appropriate tissue handling and transport. Regulatory reporting is not typically required for PLE, but clinicians should be aware that chronic granulomatous enteritis in ruminants caused by paratuberculosis has production implications and may be subject to surveillance requirements under international animal health standards WOAH terrestrial animal health standards.

Frequently Asked Questions

How Do I Proceed When Intestinal Biopsy Is Not Feasible Due to Cost or Patient Risk?

When full-thickness or endoscopic biopsy is not possible, a treatment trial becomes the diagnostic instrument. Begin with a strict elimination diet for 2 to 3 weeks, then add an antimicrobial trial if response is incomplete. Glucocorticoids are reserved for nonresponders, as their use can obscure a subsequent histologic diagnosis. Serial albumin, C-reactive protein, and clinical activity index scores provide objective monitoring. A durable response to dietary change supports food-responsive enteropathy, whereas relapse on glucocorticoid withdrawal suggests inflammatory disease. Remember that ultrasonographic findings such as hyperechoic mucosal striations support, but do not confirm, protein-losing enteropathy, as described in a comparison of ultrasonographic findings with clinical activity index and diagnosis in dogs with chronic enteropathies. Document the treatment ladder explicitly in the record so a future clinician understands which interventions have already failed.

What Minimum Laboratory Panel Is Acceptable When Budget Is Constrained?

A minimum database must include serum albumin, globulins, cholesterol, calcium, and a complete blood count. Add urine protein to creatinine ratio and fasting serum bile acids or pre- and postprandial bile acids to exclude renal and hepatic protein loss. Serum cobalamin and folate are valuable because concurrent deficiency affects both diagnostic interpretation and response to therapy. If pancreatic lipase immunoreactivity is unaffordable, a fecal proteolytic activity test on a fresh sample offers a crude screen for exocrine pancreatic insufficiency, though it is less sensitive. Skip vitamin D measurement if funds are limited, but recognize that low 25-hydroxyvitamin D concentration carries prognostic weight, as shown in a retrospective study of 43 dogs with protein-losing enteropathy. Recheck albumin within 2 weeks, a rising trend validates the diagnostic path even when advanced testing was not possible.

How Does the Diagnostic Approach Differ in Cats Compared With Dogs?

Feline protein-losing enteropathy is uncommon, and the index of suspicion should remain lower than in dogs. Chronic enteropathy in cats more often presents with weight loss and vomiting than with overt diarrhea, and ascites is rare. The same exclusion sequence applies: rule out renal and hepatic disease first, then pancreatic insufficiency, which is genuinely uncommon in cats. Intestinal biopsy is indicated earlier in cats because alimentary lymphoma is a frequent cause of protein loss, and a treatment trial that fails can delay lymphoma diagnosis by weeks. Histopathology should include immunophenotyping and clonality testing when lymphoma is suspected, because the distinction between severe lymphocytic enteritis and small-cell lymphoma is histologically challenging. The ACVIM consensus statements provide species-specific guidance on chronic enteropathy diagnosis that differs meaningfully from the canine framework.

What Should I Document to Support a Defensible Diagnosis Over Time?

Record the date of every albumin measurement, the clinical activity index score, body weight, and the current treatment and dose. Note the specific diet fed, including manufacturer and formula, because diet changes confound interpretation of response. Document the rationale for each diagnostic step and the result, including negative findings. When biopsy is declined, record that the option was discussed and the reason for refusal. Serial albumin trends matter more than single values, so plot them in the record. If the patient is referred, send the complete timeline, also the latest bloodwork. The MSD Veterinary Manual advises that monitoring parameters be defined at the outset of treatment so that response is judged against a pre-set threshold instead of a subjective impression. This documentation also supports accurate communication with the owner about prognosis.

How Do I Explain the Diagnostic Uncertainty to an Owner Who Wants a Definitive Answer?

Frame the workup as a sequence of exclusions, each step narrowing the possibilities. Explain that blood tests confirm protein loss from the gut but cannot identify the exact cause, and that biopsy is the only way to distinguish inflammatory disease from lymphoma or lymphangiectasia. Use the analogy of a biopsy as a photograph of the intestine at one moment, acknowledging that patchy disease can be missed. State plainly that some dogs respond to treatment without a confirmed histologic diagnosis, and that the treatment trial itself provides diagnostic information. Cite the prognostic data honestly: in one cohort of Yorkshire Terriers, only 12 of 23 dogs with follow-up achieved complete or partial resolution of signs, so expectations should be realistic. Offer the owner a written summary of the diagnostic plan and the decision points ahead.

When Should I Refer the Case instead of Continue Managing It in Primary Care?

Refer when the patient deteriorates despite appropriate treatment, when albumin falls below 1.5 g/dL, or when ascites or respiratory difficulty develops, as these signs carried poor prognostic weight in a study of Yorkshire Terriers with protein-losing enteropathy. Refer early if you lack access to endoscopic biopsy, pancreatic lipase immunoreactivity, or vitamin D measurement, because these results change management. Cases with suspected intestinal lymphoma warrant specialist evaluation for immunophenotyping and clonality testing. Refer also when the owner requests a second opinion or when you have reached the limit of your therapeutic options and the patient is not improving. A retrospective study of 92 dogs identified high clinical activity index scores, clonal lymphocyte receptor rearrangement, and elevated blood urea nitrogen as independent predictors of mortality, so any of these findings should lower your threshold for referral.

Related Clinical & Scientific Guides

• Feline Hepatic Lipidosis: Nutritional and Medical Management
• Canine Respiratory Infection: Diagnostic Approach and Treatment
• Canine Respiratory Virus: Diagnostic and Management Considerations

References and Further Reading

• Clinical features, intestinal histopathology, and outcome in protein-losing enteropathy in Yorkshire Terrier dogs.. 2014.
• Comparative pathophysiology and management of protein-losing enteropathy.. 2019.
• Prognostic factors in dogs with protein-losing enteropathy.. 2015.
• Comparison of ultrasonographic findings with clinical activity index (CIBDAI) and diagnosis in dogs with chronic enteropathies.. 2008.
• The effect of paratuberculosis on milk yield--A systematic review and meta-analysis.. 2016.
• Hypovitaminosis D is associated with negative outcome in dogs with protein losing enteropathy: a retrospective study of 43 cases.. 2017.
• ACVIM Consensus Statements. Journal of Veterinary Internal Medicine.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.
• American Veterinary Medical Association Practice Resources. American Veterinary Medical Association.

Related Articles

• Canine Proteinuria: Diagnostic Approach and Management
• Canine Vomiting: Diagnostic Approach and Management
• Feline Chronic Enteropathy: Diagnostic and Management Framework
• Feline Immune-Mediated Disease: Diagnostic Approach and Management
• Canine Immune-Mediated Polyarthritis: Diagnostic Approach and Management

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.